ArticleMedicine2026
Mortality trends and projections for type 2 diabetes with concomitant Parkinson's versus Alzheimer's disease among older United States adults, 1999-2023: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Although type 2 diabetes mellitus (T2DM) frequently co-occurs with Parkinson's disease (PD) and Alzheimer's disease (AD), a systematic comparison of their combined mortality burdens remains lacking. This study aimed to compare long-term mortality trends and project future burdens among older US adults with T2DM comorbid with either PD or AD. A retrospective cohort study was conducted using national mortality data (1999-2023) from the CDC WONDER database. Decedents were identified using ICD-10 codes for T2DM with PD (E11 + G20) or AD (E11 + G30). Temporal trends were analyzed to estimate annual percentage change (APC) and average annual percentage change (AAPC), and future age-adjusted mortality rates were projected through 2030. Both conditions exhibited sustained upward mortality trends from 1999 to 2023, with T2DM with PD showing higher relative growth (AAPCs) but lower absolute burden than T2DM with AD. The steepest increases in death counts occurred among Hispanic/Latino individuals and in the Western United States, while the highest AAPCs in age-adjusted mortality were seen among Hispanic/Latino adults with T2DM and AD and in the Western United States for both conditions. Males had higher age-adjusted mortality for T2DM with PD, whereas females had higher absolute death counts for T2DM with AD. Mortality for T2DM with PD peaked at ages 75 to 84, while for T2DM with AD it rose continuously with age. A marked shift from institutional to home-based deaths was observed. Projections indicate age-adjusted mortality will exceed 2023 levels by over 20% by 2030, reaching 6.66 (T2DM with PD) and 15.99 (T2DM with AD) per 1,00,000. Mortality associated with T2DM comorbid with PD or AD is escalating, characterized by distinct demographic and geographic disparities. These findings underscore the urgent need for integrated clinical screening, stratified prevention strategies, and strengthened community-based care to mitigate the growing burden of these complex multimorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.